Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis.
Walker
S
S
Imperial College School of Medicine, Harefield Hospital, Middlesex, United Kingdom.
Habib
S
S
Rose
M
M
Yacoub
M
M
Banner
N
N
D001682:Biological Availability; D001989:Bronchiolitis Obliterans / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000601:surgery*; D005500:Follow-Up Studies; D016041:Heart-Lung Transplantation / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016040:Lung Transplantation / Q000276:immunology* / Q000502:physiology; D011183:Postoperative Complications; D012189:Retrospective Studies; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus